Adjuvant Therapy Clinical Trials

11 recruiting

Adjuvant Therapy Trials at a Glance

69 actively recruiting trials for adjuvant therapy are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 2 with 28 trials, with the heaviest enrollment activity in Shanghai, Shanghai, and Chengdu. Lead sponsors running adjuvant therapy studies include Fudan University, Sun Yat-sen University, and West China Hospital.

Browse adjuvant therapy trials by phase

Treatments under study

About Adjuvant Therapy Clinical Trials

Looking for clinical trials for Adjuvant Therapy? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Adjuvant Therapy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Adjuvant Therapy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 69 trials

Recruiting
Not Applicable

Digital Mind-Body Therapy for Neoadjuvant Breast Cancer

Neoadjuvant Therapy
Fudan University66 enrolled1 locationNCT07541664
Recruiting

Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:

Adjuvant TherapyCDK4/6 Inhibitor
European Institute of Oncology750 enrolled18 locationsNCT07180693
Recruiting

Circulating microRNAs and Response to Neoadjuvant Chemotherapy in Breast Cancer

Breast CancerNeoadjuvant TherapyInvasive Breast Carcinoma+2 more
Atlas University80 enrolled1 locationNCT07289282
Recruiting
Phase 2

CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer

Neoadjuvant TherapyLocally Advanced Rectal Cancer
Fudan University192 enrolled1 locationNCT06281405
Recruiting
Phase 2

Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC

Neoadjuvant TherapyKRAS G12C MutationResectable NSCLC+1 more
Jianxing He30 enrolled3 locationsNCT07492342
Recruiting

Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer(NSCLC)

Neoadjuvant TherapyNSCLC
Qian Chu500 enrolled2 locationsNCT07388771
Recruiting
Phase 1

An Antibody-armored Dendritic Cell in Patients With Solid Tumors

Adjuvant TherapySolid Cancers
Shanghai Cell Therapy Group Co.,Ltd8 enrolled1 locationNCT07479667
Recruiting
Phase 2

Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer

Neoadjuvant TherapyImmunotherapyTislelizumab+3 more
Seventh Medical Center of PLA General Hospital50 enrolled1 locationNCT07458529
Recruiting

To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)

Neoadjuvant TherapyLung NeoplasmsMinimal Residual Disease+1 more
Peking University People's Hospital100 enrolled1 locationNCT07291921
Recruiting
Phase 2

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8+26 more
M.D. Anderson Cancer Center50 enrolled1 locationNCT04771520
Recruiting
Phase 1

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Locally Advanced Gastroesophageal Junction AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaStage IV Colorectal Cancer AJCC v8+26 more
Roswell Park Cancer Institute45 enrolled1 locationNCT04511039
Recruiting

Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer

Bladder CancerBladder Cancer RecurrenceAdjuvant Therapy for Bladder Cancer+1 more
Zhilong Dong400 enrolled1 locationNCT07424560
Recruiting

Perioperative Outcomes After Neoadjuvant Therapy in Colorectal Cancer

Neoadjuvant TherapyColorectal Carcinoma (CRC)Complications+1 more
Osijek University Hospital68 enrolled1 locationNCT07422974
Recruiting
Phase 2

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Neoadjuvant TherapyClear Cell Renal Cell CarcinomaIparomlimab and Tuvonralimab
Sun Yat-sen University25 enrolled1 locationNCT07389629
Recruiting
Not Applicable

Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study

Breast CancerProstate CancerNeoadjuvant Therapy+2 more
Mälardalen University172 enrolled2 locationsNCT06719206
Recruiting
Phase 3

No Axillary Surgical Treatment in Clinically Lymph Node Negative Patients on Ultrasonography After Neoadjuvant Chemotherapy

Breast CancerNeoadjuvant TherapySentinel Lymph Node Biopsy
Seoul National University Hospital464 enrolled1 locationNCT06704945
Recruiting
Phase 3

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

Breast CancerAdjuvant Therapy
Fudan University1,903 enrolled1 locationNCT07019363
Recruiting
Phase 2

Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma

Hepatocellular CarcinomaNeoadjuvant TherapySintilimab+1 more
Sun Yat-sen University37 enrolled1 locationNCT07324824
Recruiting
Early Phase 1

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+30 more
M.D. Anderson Cancer Center15 enrolled1 locationNCT05041153
Recruiting

Sleeve Lobectomy Following Neoadjuvant Therapy in NSCLC

Lung CancerNeoadjuvant Therapy
Shanghai Chest Hospital400 enrolled1 locationNCT07135856